American Shared Hospital Services

American Shared Hospital Services(AMS)の株式分析

$1.260

-0.010 (-0.79%)終値時点

Loading chart…
高値
1.290
始値
1.290
出来高加重平均価格
1.27
出来高
2.64K
時価総額
20.46M
安値
1.260
売買代金
3.35K
EV/EBITDA(TTM)
0.00

American Shared Hospital Services is a provider of turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. Its segments include Leasing and Retail. The Leasing segment comprises the Company’s medical equipment leasing. The Retail segment comprises facilities in Peru and Ecuador. Its Proton Beam Radiation Therapy Operations is an alternative to traditional external beam, photon-based radiation delivered by linear accelerators. Its Gamma Knife stereotactic radiosurgery, a non-invasive procedure, is an alternative to conventional brain surgery and/or radiation therapy. The Gamma Knife treats selected malignant and benign brain tumors, arteriovenous malformations, and functional disorders including trigeminal neuralgia (facial pain). It can be an adjunct to conventional brain surgery, radiation therapy, or chemotherapy. The Company provides radiation therapy services both domestically and internationally.

ashs.com

AI分析 of American Shared Hospital Services (AMS)

中立

American Shared Hospital Services (AMS) is currently not a strong buy due to its low RSI of 24.755, indicating oversold conditions, and a significant year-to-date change of -37.22%. While the recent revenue growth of 19.2% year-over-year in Q2 2026 is promising, the company has been consistently reporting net losses, with a net income of -612,000 USD in Q1 2026 and -998,000 USD in Q2 2026. The forward P/E ratio of 44.64 suggests that the stock may be overvalued relative to its earnings potential. The main risk is the continued decline in stock price, as evidenced by a 5-day change of -6.38%.

バリュエーション指標

American Shared Hospital Services(AMS)の現在の予想PERは44.64で、5年平均は13.34です。

予想PER

割高
5年平均 P/E
13.34
現在のP/E
44.64
割高
38.87
割安
-12.19

予想EV/EBITDA

大幅な割安
5年平均 EV/EBITDA
0.00
現在のEV/EBITDA
0.00
割高
0.00
割安
0.00

予想PSR

割安
5年平均 P/S
0.48
現在のP/S
0.00
割高
0.80
割安
0.16

Alphio AI による AMS の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%AMS

$3.00

シナリオ価格

基

基本

基本 · 50%AMS

$2.96

シナリオ価格

弱

弱気

弱気 · 25%AMS

$2.19

シナリオ価格

イベントタイムライン

2025-12-01 (ET)

05:29:00

JPMorgan Downgrades ams OSRAM to Underweight, Price Target Cut to CHF 5.35

2025-11-13 (ET)

07:04:59

American Shared Hospital Announces Q3 EPS of 0c Compared to (3c) Last Year

2025-08-13 (ET)

07:07:11

American Shared Hospital reports Q2 EPS (4c) vs. 55c last year

2025-05-15 (ET)

07:02:10

American Shared Hospital reports Q1 EPS (10c) vs 2c last year

2025-04-04 (ET)

07:04:18

American Shared Hospital appoints Gary Delanois as CEO

ニュース

AMS のよくある質問 — Alphio AI が回答

American Shared Hospital Services is a provider of turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. Its segments include Leasing and Retail. The Leasing segment comprises the Company’s medical equipment leasing. The Retail segment comprises facilities in Peru and Ecuador. Its Proton Beam Radiation Therapy Operations is an alternative to traditional external beam, photon-based radiation delivered by linear accelerators. Its Gamma Knife stereotactic radiosurgery, a non-invasive procedure, is an alternative to conventional brain surgery and/or radiation therapy. The Gamma Knife treats selected malignant and benign brain tumors, arteriovenous malformations, and functional disorders including trigeminal neuralgia (facial pain). It can be an adjunct to conventional brain surgery, radiation therapy, or chemotherapy. The Company provides radiation therapy services both domestically and internationally. It operates in the Industrials sector (SERVICES-MEDICAL LABORATORIES industry).

American Shared Hospital Services (AMS) is currently not a strong buy due to its low RSI of 24.755, indicating oversold conditions, and a significant year-to-date change of -37.22%. While the recent revenue growth of 19.2% year-over-year in Q2 2026 is promising, the company has been consistently reporting net losses, with a net income of -612,000 USD in Q1 2026 and -998,000 USD in Q2 2026. The forward P/E ratio of 44.64 suggests that the stock may be overvalued relative to its earnings potential. The main risk is the continued decline in stock price, as evidenced by a 5-day change of -6.38%.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める